The decision comes after Genentech reported a fourth case of PML diagnosed in a 47 year old man in Germany in February,
and a subsequent warning by the FDA. Three other people taking
Raptiva have developed PML, two of whom died.
Raptiva is an antibody therapy that reduces psoriasis flare-ups by suppressing T-cells. Sales of the drug were $108 million in 2008, and about 2,000 people are currently taking it, according to a statement by Genentech.